Cure My Disease

Don't miss your cure!

 Log in / Sign up

Vaccine link to thyroid disease under investigation

NCT ID NCT07213141

Knowledge-focused Sponsor: Laura ICONARU Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether COVID-19 vaccination might trigger Graves' disease, a condition where the immune system attacks the thyroid. Researchers will review medical records of 161 people who developed Graves' disease for the first time between March 2020 and October 2022. They want to see if cases that happened shortly after vaccination are different from typical cases, which could help doctors better diagnose and treat the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

161 people

The number who actually took part.

Started

Nov 2022

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients who developed 'de novo' Graves' disease between March 2020 (the beginning of the COVID-19 epidemic in Belgium) and October 2022. These patient cases will be identified based on the biochemical-radiological factors diagnostic for "classic" Graves' disease, i.e., hyperthyroidism in the context of positivity for TSI and/or homogeneous captation on thyroid scintigraphy

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: All patients who developed 'de novo' Graves' disease between March 2020 (the beginning of the COVID-19 epidemic in Belgium) and October 2022. Exclusion Criteria: * Pregnancy * Pre-existing Graves' disease (before March 2020) * Diagnosis of other thyroid disease, such as subacute or painless destructive thyroiditis * Use of thyroid-interfering drugs, such as lithium, amiodarone or immune checkpoint inhibitor therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Graves disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Graves disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Graves disease

Contacts and locations

Locations

  • CHU Brugmann

    Brussels, 1020, Belgium

  • CHU St Pierre

    Brussels, 1000, Belgium

  • UZ Brussel

    Jette, 1090, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.